Drug Trial Radar · NCT07308574
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Jun 25, 2027
Study completion Jun 25, 2027
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
Conditions
- aHUS
- Atypical Hemolytic Uremic Syndrome
Interventions
RavulizumabDrug
Participants will receive ravulizumab via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Showing Improvement in Platelet Count During the 26-week Ravulizumab TreatmentTime frame: Baseline up to Week 26
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Bunkyō City, Japan · Not yet recruiting
Research Site
Hirakata-shi, Japan · Not yet recruiting
Research Site
Iruma-Gun, Japan · Recruiting
Research Site
Kyoto, Japan · Not yet recruiting
Research Site
Matsumoto-shi, Japan · Not yet recruiting
Research Site
Miyazaki, Japan · Not yet recruiting
Research Site
Nagoya, Japan · Recruiting
Research Site
Nara, Japan · Not yet recruiting
Research Site
Nerima-ku, Japan · Not yet recruiting
Research Site
Sapporo, Japan · Not yet recruiting
Research Site
Shinjuku-ku, Japan · Not yet recruiting
Research Site
Tsu, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.